KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), development-stage oncology and dermatology biopharmaceutical company, announced that the lead investigator for its Phase 2 melanoma study, Professor John F. Thompson, MD, will present clinical data on PV-10 at the Clinical Oncological Society of Australia (COSA) 2008 Annual Scientific Meeting (ASM) in Sydney, Australia. Professor Thompson's presentation, entitled "Chemoablation of Cutaneous and Subcutaneous Metastatic Melanoma Using PV-10," is scheduled for the afternoon of November 19th. One of the main focuses of the COSA meeting this year is melanoma.
